What Is an Aneuploid Embryo and What Happens Next?

An aneuploid embryo is one that has the wrong number of chromosomes, either too many or too few. Where a typical human embryo carries 46 chromosomes arranged in 23 pairs, an aneuploid embryo might have 45, or 47, or some other count that throws off the genetic blueprint. In the context of IVF, finding out that an embryo is aneuploid is surprisingly common and does not necessarily mean there are zero options left, though it does fundamentally change the conversation about next steps.

How Aneuploidy Happens in the First Place

Most chromosome errors in embryos trace back to the egg. During the process that creates a mature egg, chromosomes must line up and separate precisely. The machinery responsible for pulling chromosomes apart is a structure called the spindle, and in human eggs, it is prone to making mistakes. Microtubules within the spindle frequently attach to chromosomes in the wrong orientation, leading to uneven separation. Multiple features of how the human egg spindle is built make these incorrect attachments more likely, including inherent instability in the spindle itself.¹

Maternal age amplifies the problem. The molecular “glue” that holds paired chromosomes together deteriorates over time. Research on human eggs shows that the distance between paired chromosome structures increases with a woman’s age, indicating weakened cohesion, and that completely unpaired chromosomes appear in eggs from older women.² Beyond cohesion loss, multiple age-related mechanisms pile on: the cell’s quality-control checkpoint becomes less reliable, energy-producing structures within the egg decline, and chemical modifications to the proteins that package DNA become abnormal.³ The cumulative effect is dramatic. By the early forties, more than half of a woman’s embryos may be aneuploid; by the mid-forties, the majority are.

Sperm can contribute, too, though they play a smaller role. Men with severe sperm abnormalities produce embryos with higher rates of chromosome errors. In one study, the proportion of chromosomally abnormal embryos was about 55% in couples with normal sperm, 62% in couples with low sperm counts and motility, and 69% when sperm had to be surgically retrieved due to blocked or absent production.⁴ Couples with abnormal sperm fluorescence testing results also showed patterns suggesting sperm-driven aneuploidy.⁵

How Aneuploidy Is Detected During IVF

The standard way clinics screen for aneuploidy is called preimplantation genetic testing for aneuploidy, or PGT-A. The embryo is grown in the lab for five to seven days until it reaches the blastocyst stage, at which point it has two distinct cell populations: an outer shell of cells called the trophectoderm, which will become the placenta, and an inner cell mass, which will become the baby. A laser opens a small hole in the embryo’s outer coating, and five to eight trophectoderm cells are carefully removed for genetic analysis.⁶ The inner cell mass is left untouched, which makes the procedure less invasive than earlier methods that sampled the embryo at day three.

The technology behind PGT-A has changed substantially since the 1990s. Early versions used a technique that could only examine a handful of chromosomes at a time. Modern methods, including next-generation sequencing, screen all 23 chromosome pairs simultaneously and can detect not just full chromosome gains or losses but also partial changes and mosaicism.⁷

The embryo is frozen after biopsy while the lab processes the sample. Results come back classifying each embryo as euploid (normal chromosome count), aneuploid (abnormal), or mosaic (a mixture of normal and abnormal cells). That three-way classification is where the clinical decision-making gets complicated.

The Accuracy Problem With Biopsy Results

A trophectoderm biopsy samples the placental precursor cells, not the cells that will form the baby. That distinction matters because those two cell populations do not always match. One study found that the overall rate of “confined mosaicism,” where the trophectoderm and inner cell mass gave different results, was about 14%.⁸ An earlier analysis using a different technology found lower discordance, with only about 4% of blastocysts showing different results between the inner cell mass and trophectoderm.⁹

From a practical standpoint, the clinical concordance is better than the raw numbers suggest. In embryos where the trophectoderm biopsy showed high-level mosaicism or full aneuploidy, about 86% of the time the inner cell mass was also high-mosaic or abnormal. And in embryos with a normal or low-mosaic biopsy, about 88% had a normal or low-mosaic inner cell mass.¹⁰ So the test gets the big-picture call right most of the time, but it is not perfect, and that imperfection is a real source of anguish for patients who are told their only embryos are aneuploid.

What Happens to Fully Aneuploid Embryos

Embryos with a uniform whole-chromosome aneuploidy, meaning every cell in the biopsy sample shows the same extra or missing chromosome, very rarely result in the live birth of a healthy baby. Transferring them exposes women to significant risks of miscarriage and chromosomally abnormal pregnancy.¹¹ This is consistent with what we know about early pregnancy more broadly: chromosome abnormalities cause more than half of all first-trimester miscarriages, with the vast majority being numerical errors like the ones PGT-A detects.¹²

Some specific aneuploidies are compatible with a live birth but cause serious conditions. Trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome) are the most well-known. Certain sex chromosome abnormalities can also result in live-born children with varying degrees of health impact. Most other full trisomies or monosomies (aside from monosomy X, or Turner syndrome) are lethal so early in development that they never produce a recognizable pregnancy.

Because of these risks, clinics strongly advise against transferring embryos with aneuploidies known to be compatible with live birth of a significantly affected child. Some institutions will proceed after intensive counseling and a signed informed-consent document acknowledging the decision goes against medical advice, but only when patients have no realistic alternatives and fully understand the risks involved.¹³

Mosaic Embryos and Why They Complicate Everything

Mosaicism is the gray zone. A mosaic embryo contains a mixture of chromosomally normal and abnormal cells. This is not rare. Chromosomal instability is a well-documented feature of early human development, driven by altered cell-cycle checkpoints, centrosome problems, and cohesion failures that mirror mechanisms seen in cancer biology.¹⁴ Across multiple mammalian species, frequent chromosomal errors and developmental failure in early embryos appear to be the norm rather than the exception, with mice being the unusual outlier.¹⁵

The critical question for patients is whether a mosaic embryo can self-correct. Several pathways for correction have been proposed: abnormal cells may be selectively destroyed, physically pushed out of the developing embryo, shunted into the trophectoderm (the future placenta rather than the baby), or undergo “rescue” events where a trisomic cell loses the extra chromosome during a later division.¹⁶ Research has found direct physical evidence of this correction: when researchers analyzed the cellular debris shed by embryos during development, they found cases where the blastocyst was euploid but the expelled debris contained aneuploid cells, suggesting the embryo had actively ejected its chromosomally abnormal cells.¹⁷

In some embryos, though, no correction occurs, and aneuploid cell lines persist.¹⁸ Clinicians cannot tell in advance which mosaic embryos will self-correct and which will not, which is what makes the transfer decision so difficult.

Transferring Mosaic Embryos

When patients have no euploid embryos available, mosaic embryo transfer becomes a real conversation. The clinical data so far is cautiously reassuring. Studies comparing outcomes after transfer of mosaic versus euploid embryos have found that rates of clinical pregnancy, pregnancy loss, and obstetric complications did not differ significantly between the two groups.¹⁹ Among women who had a live birth after mosaic embryo transfer and went on to have prenatal or postnatal genetic testing, no abnormalities were found.²⁰

These are encouraging numbers, but they come with caveats. The studies are still relatively small, and not every pregnancy after mosaic transfer includes confirmatory genetic testing of the baby. Most clinics rank mosaic embryos by level of mosaicism and which chromosomes are involved, transferring low-mosaic embryos first and avoiding those with mosaicism on chromosomes associated with viable trisomies like 21 or 18. Prenatal testing during the resulting pregnancy is strongly recommended.

Prenatal Monitoring After Any Embryo Transfer

Even after transferring a euploid embryo, prenatal screening adds a layer of reassurance and occasionally catches something unexpected. In a study of over 1,100 patients who had noninvasive prenatal testing (a blood test during pregnancy) after transferring a PGT-A-normal embryo, eight received a positive screen. Of those, six turned out to be false alarms confirmed by further testing. One patient skipped follow-up testing and delivered a normal baby. But one case was confirmed as Turner syndrome mosaicism on amniocentesis, giving the noninvasive blood test a positive predictive value of just 12.5% in this group.²¹

The takeaway is that PGT-A and prenatal blood screening are complementary but imperfect tools, and neither one alone guarantees a chromosomally normal pregnancy. When prenatal screening flags something after a euploid embryo transfer, diagnostic testing like amniocentesis is the next step to sort out whether it is a true finding or a false positive.

What Patients Can Do With Aneuploid Embryos

For embryos that come back clearly aneuploid, patients face a decision that is practical and deeply personal at the same time. In a survey of IVF patients who had aneuploid or affected embryos, about 84% said they would choose to donate them to research, about 9% would discard them, and only 7% would keep them frozen indefinitely. The dominant motivation for donation was an altruistic desire to advance IVF and stem cell research.²² That said, the survey’s response rate was modest, and people who feel strongly about donation may have been more likely to respond.

Some patients request transfer of aneuploid embryos anyway, particularly when they have exhausted all other options and do not wish to pursue further egg retrieval cycles. Clinics handle these requests with intensive counseling and institutional policies that vary. Embryos with aneuploidies incompatible with life, like most full autosomal trisomies, will almost certainly fail to implant or will miscarry early. Embryos with aneuploidies compatible with live birth present the more ethically charged dilemma, because a successful pregnancy could result in a child with a serious chromosomal condition.

Lab Conditions and Their Surprising Influence

One underappreciated factor is that the IVF lab environment itself may affect aneuploidy rates. Culture medium composition, pH, temperature, oxygen levels, and osmolality could all influence how chromosomes behave during the early cell divisions after fertilization. Even the method used to introduce sperm to the egg and the laser energy used during biopsy might affect genetic results.²³ This does not mean lab-induced aneuploidy is a major driver compared to the inherent biology of egg and sperm, but it does mean that lab quality matters in ways patients rarely think about when choosing a clinic.

The Emotional Weight of PGT-A Results

Getting results back from PGT-A can be one of the most stressful moments in an already stressful process. Research on the psychological impact found that having fewer euploid embryos was associated with greater decision regret about pursuing testing in the first place. Patients who conceived after transferring a euploid embryo reported less regret than those who miscarried or failed to conceive. Anxiety was significantly higher following a negative pregnancy test or miscarriage compared to successful conception.²⁴ Overall, about 94% of respondents said they were satisfied with their decision to pursue PGT-A, but the data also showed that satisfaction correlated heavily with a good outcome, and people with negative results carried a heavier emotional burden.

The hardest scenario is when PGT-A reveals that every embryo from a cycle is aneuploid. This is not uncommon for women over 40 and can lead to the painful decision of whether to try another retrieval cycle, switch strategies entirely, or stop treatment. Knowing in advance that this is a possibility, and having discussed it with a counselor or reproductive endocrinologist, can soften the blow somewhat but does not eliminate it.

The Cost Equation

PGT-A adds several thousand dollars to an IVF cycle, and whether it represents good value depends heavily on the patient’s age and how many embryos they produce. For patients younger than 35, one analysis found that PGT-A was associated with worse clinical outcomes and higher costs, likely because younger patients produce enough good embryos that testing and freezing each one adds expense without meaningfully improving the overall chance of having a baby.²⁵ Starting around age 38 or 39, the economics shifted in favor of PGT-A from the patient’s perspective. A separate study found that for patients with more than one embryo, PGT-A reduced overall treatment costs and shortened time in treatment by up to four months, while also reducing the number of failed transfers and clinical miscarriages.²⁶

Cost-effectiveness improves with female age and the number of available blastocysts.²⁷ For a 30-year-old with eight blastocysts, testing each one adds cost without clearly improving cumulative birth rates. For a 41-year-old with three blastocysts, PGT-A helps identify the one most likely to work and avoids weeks of hormonal preparation and emotional investment in transfers destined to fail.

Non-Invasive Alternatives on the Horizon

Researchers are developing ways to test embryo DNA without physically removing any cells. The approach, sometimes called non-invasive PGT-A, analyzes fragments of DNA that the embryo naturally sheds into the liquid it grows in during culture. One study found an overall concordance rate of about 82% between this non-invasive method and standard biopsy-based testing, with agreement on aneuploid embryos reaching about 92%.²⁸

Some research has even suggested that non-invasive testing from spent culture medium may be more reliable than trophectoderm biopsy for matching the embryo’s true chromosome status, because the DNA in the medium may better represent the whole embryo rather than just the outer cell layer.²⁹ The technology is not ready for routine clinical use yet. Concordance rates need to improve further, and contamination from maternal DNA in the culture medium remains a technical challenge. But the promise of eliminating the biopsy step entirely, and potentially getting a more accurate picture of the embryo’s genetic makeup, makes this one of the most actively pursued areas in reproductive genetics.